Prosthetic valve thrombosis: a regimen of treatment with low-dose and longer-course using recombinant tissue-type plasminogen activator is a promising protocol.
Cáceres-Lóriga
Fidel Manuel
FM
Pérez-López
Horacio
H
Morlans-Hernández
Karel
K
D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006350:Heart Valve Prosthesis / Q000009:adverse effects*; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects* / Q000379:methods; D006801:Humans; D007262:Infusions, Intravenous; D011183:Postoperative Complications / Q000175:diagnosis / Q000188:drug therapy; D020127:Recovery of Function; D012680:Sensitivity and Specificity; D013927:Thrombosis / Q000188:drug therapy* / Q000209:etiology; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator